This study tests ecopipam tablets for treating Tourette's Disorder (TD), a condition with repeated movements or sounds. It is a Phase 3 study, meaning it is in advanced testing stages. Participants will first try ecopipam in an open-label phase, where they know what they're taking, adjusting the dose over 4 weeks. Then, for 8 weeks, they will stay on this dose. Next, participants will either continue ecopipam or switch to a placebo (a pill with no medicine) without knowing which they're taking, for up to 12 weeks. This part is called double-blind, where neither the participants nor the researchers know who gets the real medicine. Participants will have regular check-ups and can leave the study if their symptoms return. Eligible participants must be at least 6 years old, weigh over 18 kg (about 40 lbs), and have both motor and vocal tics. They must not have been on other tic medications recently.

• Study lasts about 24 weeks in total
• Participants must attend multiple visits
• Regular follow-ups and safety checks included